Ionis announces eplontersen receives orphan drug designation from U.S. FDA
- Monday, January 24, 2022, 7:08
- Finance
- Add a comment
CARLSBAD, Calif., Jan. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for…
About the Author
adminasapcorp has written 41555 stories on this site.